Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).

PD-related infection Peritoneal Dialysis and Outcomes Practice Patterns Study (PDOPPS) Peritoneal dialysis (PD) bacterial infection best practices causative organism epidemiology facility practices hospitalization international comparisons microbiology peritonitis peritonitis prevention technique failure

Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
07 2020
Historique:
received: 11 04 2019
accepted: 24 09 2019
pubmed: 15 1 2020
medline: 30 9 2020
entrez: 15 1 2020
Statut: ppublish

Résumé

Peritoneal dialysis (PD)-related peritonitis carries high morbidity for PD patients. Understanding the characteristics and risk factors for peritonitis can guide regional development of prevention strategies. We describe peritonitis rates and the associations of selected facility practices with peritonitis risk among countries participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Observational prospective cohort study. 7,051 adult PD patients in 209 facilities across 7 countries (Australia, New Zealand, Canada, Japan, Thailand, United Kingdom, United States). Facility characteristics (census count, facility age, nurse to patient ratio) and selected facility practices (use of automated PD, use of icodextrin or biocompatible PD solutions, antibiotic prophylaxis strategies, duration of PD training). Peritonitis rate (by country, overall and variation across facilities), microbiology patterns. Poisson rate estimation, proportional rate models adjusted for selected patient case-mix variables. 2,272 peritonitis episodes were identified in 7,051 patients (crude rate, 0.28 episodes/patient-year). Facility peritonitis rates were variable within each country and exceeded 0.50/patient-year in 10% of facilities. Overall peritonitis rates, in episodes per patient-year, were 0.40 (95% CI, 0.36-0.46) in Thailand, 0.38 (95% CI, 0.32-0.46) in the United Kingdom, 0.35 (95% CI, 0.30-0.40) in Australia/New Zealand, 0.29 (95% CI, 0.26-0.32) in Canada, 0.27 (95% CI, 0.25-0.30) in Japan, and 0.26 (95% CI, 0.24-0.27) in the United States. The microbiology of peritonitis was similar across countries, except in Thailand, where Gram-negative infections and culture-negative peritonitis were more common. Facility size was positively associated with risk for peritonitis in Japan (rate ratio [RR] per 10 patients, 1.07; 95% CI, 1.04-1.09). Lower peritonitis risk was observed in facilities that had higher automated PD use (RR per 10 percentage points greater, 0.95; 95% CI, 0.91-1.00), facilities that used antibiotics at catheter insertion (RR, 0.83; 95% CI, 0.69-0.99), and facilities with PD training duration of 6 or more (vs <6) days (RR, 0.81; 95% CI, 0.68-0.96). Lower peritonitis risk was seen in facilities that used topical exit-site mupirocin or aminoglycoside ointment, but this association did not achieve conventional levels of statistical significance (RR, 0.79; 95% CI, 0.62-1.01). Sampling variation, selection bias (rate estimates), and residual confounding (associations). Important international differences exist in the risk for peritonitis that may result from varied and potentially modifiable treatment practices. These findings may inform future guidelines in potentially setting lower maximally acceptable peritonitis rates.

Identifiants

pubmed: 31932094
pii: S0272-6386(19)31105-9
doi: 10.1053/j.ajkd.2019.09.016
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-53

Subventions

Organisme : AHRQ HHS
ID : R01 HS025756
Pays : United States

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Jeffrey Perl (J)

Arbor Research Collaborative for Health, Ann Arbor, MI; St Michael's Hospital, Toronto, Canada. Electronic address: jeffrey.perl@unityhealth.to.

Douglas S Fuller (DS)

Arbor Research Collaborative for Health, Ann Arbor, MI.

Brian A Bieber (BA)

Arbor Research Collaborative for Health, Ann Arbor, MI.

Neil Boudville (N)

Medical School, University of Western Australia, Perth, Australia.

Talerngsak Kanjanabuch (T)

Center of Excellence in Kidney Metabolic Disorders and Division of Nephrology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.

Yasuhiko Ito (Y)

Aichi Medical University, Nagakute, Japan.

Sharon J Nessim (SJ)

Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Canada.

Beth M Piraino (BM)

University of Pittsburgh, Pittsburgh, PA.

Ronald L Pisoni (RL)

Arbor Research Collaborative for Health, Ann Arbor, MI.

Bruce M Robinson (BM)

Arbor Research Collaborative for Health, Ann Arbor, MI.

Douglas E Schaubel (DE)

Department of Biostatistics, University of Michigan, Ann Arbor, MI.

Martin J Schreiber (MJ)

DaVita HealthCare Partners Inc., Denver, CO.

Isaac Teitelbaum (I)

University of Colorado, Aurora, CO.

Graham Woodrow (G)

Renal Unit, St James's University Hospital, Leeds, United Kingdom.

Junhui Zhao (J)

Arbor Research Collaborative for Health, Ann Arbor, MI.

David W Johnson (DW)

Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia; Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH